SavedAdd your journal

Journals / Moment Dergi / 2022 / Cilt: 9 - Sayı: 1

Effects of the COVID-19 Pandemic on Bladder Cancer Diagnosis and Treatment Processes; A Turkish Multicenter Study

Ünal ÖZTEKİN
Cemil BAYRAKTAR
Abdullah GÜREL
Burhan BAYLAN
İbrahim KELEŞ
Arif DEMİRBAŞ
Mustafa KARALAR
Osman GERÇEK
Ata ÖZEN
İsmail ULUS
Salih Zeki SÖNMEZ
Erol ERŞEKERCİ
Ali ÇİFT
Ahmet Emin DOĞAN
Berk Yasin EKENCİ
Mert Ali KARADAĞ
Pages
165–171
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

It was observed that the time between symptom and diagnosis was longer in MIBC than in NIMBC during both periods (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The coronavirus disease-2019 (COVID-19) pandemic effect diagnosis and treatment of certain conditions, including bladder cancer (BC).
📊
Key Findings & Data:This study aimed to evaluate the effects of the COVID-19 pandemic on BC diagnosis and treatment.
💡
Conclusion & Impact:It was observed that the time between symptom and diagnosis was longer in MIBC than in NIMBC during both periods (p
🔬Design:Research Article
📍Scope:2019 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: The coronavirus disease-2019 (COVID-19) pandemic effect diagnosis and treatment of certain conditions, including bladder cancer (BC). This study aimed to evaluate the effects of the COVID-19 pandemic on BC diagnosis and treatment. Materials and Methods: Following the approval of the ethics committee for the study, data of 869 patients who underwent surgery for BC in the 2-year period between March 1, 2019 and February 28, 2021 were analyzed retrospectively. The number of surgeries performed for BC, the time elapsed between symptoms and diagnosis, the treatments performed, and the operative pathologies were compared before and during the COVID-19 pandemic. Results: During the COVID-19 period, there was a decrease in the total number of BC surgeries compared to the pre-COVID-19 period (p=0.004). It was observed that this decrease was due to a decrease in patients newly diagnosed with BC (p=0.001) as well as the decrease in the number of primary transurethral resection for bladder tumor procedures performed. There was no difference in the tumor stages of the patients at diagnosis (p=0.9). Intracavitary Bacillus Calmette-Guérin therapy use in high-risk non-muscle invasive bladder cancers (NMIBC) patients also decreased (p=0.008) during the pandemic period. It was observed that the time between symptom and diagnosis was longer in MIBC than in NIMBC during both periods (p

🔖

Cite This Article

ÖZTEKİN, Ü., BAYRAKTAR, C., GÜREL, A., BAYLAN, B., KELEŞ, İ., DEMİRBAŞ, A., KARALAR, M., GERÇEK, O., ÖZEN, A., ULUS, İ., SÖNMEZ, S. Z., ERŞEKERCİ, E., ÇİFT, A., DOĞAN, A. E., EKENCİ, B. Y., KARADAĞ, M. A. (2022). Effects of the COVID-19 Pandemic on Bladder Cancer Diagnosis and Treatment Processes; A Turkish Multicenter Study. Moment Dergi, Cilt: 9 - Sayı: 1, 165–171. https://ajindex.com/articles/581654

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F. Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends. Eur Urol 2017;71:96-108
  2. Babjuk M, Böhle A, Burger M, Capoun O, Cohen D, Compérat EM, Hernández V, Kaasinen E, Palou J, Rouprêt M, van Rhijn BWG, Shariat SF, Soukup V, Sylvester RJ, Zigeuner R. EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. Eur Urol 2017;71:447-461
  3. Pang KH, Noon AP. Selection of patients and benefit of immediate radical cystectomy for non-muscle invasive bladder cancer. Transl Androl Urol 2019;8:101-107
  4. Ghandour R, Singla N, Lotan Y. Treatment Options and Outcomes in Nonmetastatic Muscle Invasive Bladder Cancer. Trends Cancer 2019;5:426- 439
  5. Murali-Krishnan S, Pang KH, Greco F, Fiori C, Catto JW, Vavassori VL, Esperto F; EAU-ESRU (European Associations of Urology-European Society of Residents Urologist). Bladder-sparing treatment in MIBC: where do we stand? Minerva Urol Nefrol 2019;71:101-112
  6. Director-General W. WHO director-general’s opening remarks at the media briefing on COVID-19. World Health Organization 2020
  7. Ribal MJ, Cornford P, Briganti A, Knoll T, Gravas S, Babjuk M, Harding C, Breda A, Bex A; GORRG Group, Rassweiler JJ, Gözen AS, Pini G, Liatsikos E, Giannarini G, Mottrie A, Subramaniam R, Sofikitis N, Rocco BMC, Xie LP, Witjes JA, Mottet N, Ljungberg B, Rouprêt M, Laguna MP, Salonia A, Bonkat G, Blok BFM, Türk C, Radmayr C, Kitrey ND, Engeler DS, Lumen N, Hakenberg OW, Watkin N, Hamid R, Olsburgh J, Darraugh J, Shepherd R, Smith EJ, Chapple CR, Stenzl A, Van Poppel H, Wirth M, Sønksen J, N’Dow J; EAU Section Offices and the EAU Guidelines Panels. European Association of Urology Guidelines Office Rapid Reaction Group: An Organisation-wide Collaborative Effort to Adapt the European Association of Urology Guidelines Recommendations to the Coronavirus Disease 2019 Era. Eur Urol 2020;78:21-28
  8. Esperto F, Pang KH, Albisinni S, Papalia R, Scarpa RM. Bladder Cancer at the time of COVID-19 Outbreak. Int Braz J Urol 2020;46(Suppl 1):62-68
  9. Vigliar E, Cepurnaite R, Alcaraz-Mateos E, Ali SZ, Baloch ZW, Bellevicine C, Bongiovanni M, Botsun P, Bruzzese D, Bubendorf L, Büttner R, Canberk S, Capitanio A, Casadio C, Cazacu E, Cochand-Priollet B, D’Amuri A, Eloy C, Engels M, Fadda G, Fontanini G, Fulciniti F, Hofman P, Iaccarino A, Ieni A, Jiang XS, Kakudo K, Kern I, Kholova I, Liu C, Lobo A, Lozano MD, Malapelle U, Maleki Z, Michelow P